Previous 10 | Next 10 |
Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early 2H 2023, and potential U.S. launch in 1H 2024 Announcement of data from ongoing chronic neutropenia...
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for th...
Summary Today, we revisit a late-stage clinical biopharmaceutical company called X4 Pharmaceuticals for the first time since 2019. The company is advancing its primary drug candidate against multiple indications and could garner its first FDA approval in early 2024. Will the stock r...
Penny Stocks To Buy According To Insiders Whether you’re trading higher-priced or penny stocks, the year-end trends are mixed in 2022. While some may presume tax-loss selling is going to weigh heavier, others are loading up on their current holdings. In this article, we look at a few n...
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an estimated 50,000 U.S. chronic neutropenia patient population; patient survey voices the signif...
X4 Pharmaceuticals ( NASDAQ: XFOR ) shares fell 9% premarket on Wednesday after the therapeutics firm priced an $65M securities offering. The offering includes 52.3M shares of its common stock, pre-funded warrants to purchase 6.8M shares, and accompanying Class C warrants to p...
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its previously announced underwritten public o...
X4 Pharmaceuticals ( NASDAQ: XFOR ) shares down 14.17% after-hours after the firm has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock . It expects to grant the underwriters a 30-day option to ...
4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil (P <0.0001) and absolute lymphocyte counts (P<0.0001) versus placebo ...
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at ...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...